Entering text into the input field will update the search result below

Astellas menopause drug fezolinetant meets primary endpoints in phase 3 trial

Sep. 22, 2021 8:50 AM ETAstellas Pharma Inc. (ALPMF) Stock, ALPMY StockBy: Jonathan Block, SA News Editor

Mature Woman Experiencing Hot Flush From Menopause
Highwaystarz-Photography/iStock via Getty Images

  • Astellas Pharma's (OTCPK:ALPMF) fezolinetant met co-primary endpoints in a pivotal trial for moderate to severe vasomotor symptoms ("VMS") associated with menopause.
  • Both 30 and 45 mg given daily led to a reduction in the frequency and severity

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ALPMF
--
ALPMY
--